While the US proceeds with sweeping adjustments to its immunization guidelines, a particular individual appears in a surprising turn: Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by casting doubt on coronavirus shots during the pandemic and has concentrated on potential deaths after COVID-19 immunization in her recent position at the Food and Drug Administration.
Proposed Overhauls to Childhood Vaccine Schedule
Public health authorities planned to announce sweeping revisions to the pediatric vaccination calendar recently, aligning the US with the Danish vaccine program, according to reports – a major change that would put the US at odds with much of the international standard with insufficient data for improved outcomes. The planned update has been pushed back until the new year.
Instead of Vinay Prasad, Høeg is set to speak at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth person to head the office this year.
A New Direction at the FDA
The acting appointment might represent a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon dismantling previously authorized immunizations at the FDA.
Dr. Høeg has repeatedly called for halting some pediatric vaccine recommendations in the US so as to align more like the Danish model, a nation with universal health coverage and a citizenry approximately the population of the state of Wisconsin.
In her initial public appearances, she has kept her attention on vaccination policy – traditionally the domain of Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.
Concerns Over Expertise
The appointee has no apparent track record in medication creation, regulation or management, which has been customary for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and CBER since March.
“It seems she lacks to have the requisite experience” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She has no expertise in managing a sizeable institution. She is not an expert in drug approvals.”
Past commissioners of the center would “grasp laws and regulations and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that prior appointees who ran the center have had.”
The drug center has an immense portfolio at the FDA, Woodcock emphasized.
“The public just zeroes in on the innovative therapies, but the generic drug division approves a multitude of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and more, and every single one must be supervised,” she explained. “The area you neglect, that is the part that I always told people is going to bite you.”
Additionally, a significant administrative aspect to the role, which supervises over 5,000 personnel. “It’s a enormous leadership role, if you perform it correctly,” the former official said.
Official Statement and Controversial Policies
Regarding concerns about Høeg’s fitness for the role and whether this appointment represents more teamwork among FDA leaders on vaccines, a representative said that the “questions rely on inaccurate presumptions”.
“This background aligns with the duties of her role,” the spokesperson stated, pointing to the time Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.
As acting director, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a disputed rapid medication authorization process that allegedly troubled her preceding directors. “How are these therapies being chosen for this voucher program? Who is making the calls?” Howard said. “There is a lot of secrecy happening at the FDA right now.”
Broadly speaking, he remarked, “the agency seems to be moving towards more relaxed oversight of pharmaceuticals, except for shots.”
Public History on Immunizations
Regarding immunizations, Høeg has a clearer, if troubling, track record, some experts have noted. She authored a study using unconfirmed crowd-sourced reports to assess the frequency of heart inflammation after Covid vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccines are more dangerous than they are.
Among her “desired changes” for the new federal leadership featured changing regulations for novel immunizations and halting “unnecessary” immunizations, she remarked post-election on a online show. At the FDA, Høeg has according to sources suggested barring adolescent males from receiving COVID-19 vaccines.
“She is an complete true believer who starts off with her conclusions and reverse-engineers to fit the science in a highly disingenuous, untruthful fashion,” Howard said.
Consolidating Power and a “Revenge Tour”
Dr. Høeg became part of fellow skeptics, {like|